Biotech | October 11, 2025
Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium
Several technologies for hemoglobinopathies are being transferred to commercial partners
Several technologies for hemoglobinopathies are being transferred to commercial partners
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Subscribe To Our Newsletter & Stay Updated
